Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-09-19
2006-09-19
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S326000, C546S193000, C546S210000
Reexamination Certificate
active
07109216
ABSTRACT:
The present invention relates to a group of novel 1H-imidazole derivatives, to methods for the preparation of these compounds, and to pharmaceutical compositions containing one or more of these compounds as an active component.These 1H-imidazole derivatives are potent cannabinoid-CB1receptor agonists, partial agonists or antagonists, useful for the treatment of psychiatric and neurological disorders, as well as and other diseases involving cannabinoid neurotransmission.The compounds have the general formula (I)wherein R and R1–R4have the meanings given in the specification.
REFERENCES:
patent: 4813998 (1989-03-01), Van Lommen et al.
patent: 5616601 (1997-04-01), Khanna et al.
patent: 6432984 (2002-08-01), Barth et al.
patent: 6518264 (2003-02-01), Achard et al.
patent: 6645985 (2003-11-01), Barth et al.
patent: 6858603 (2005-02-01), Achard et al.
patent: 6906080 (2005-06-01), Barth et al.
patent: 6960601 (2005-11-01), Smith et al.
patent: 2004/0039024 (2004-02-01), Barth et al.
patent: 2004/0235816 (2004-11-01), Achard et al.
patent: 2004/0248956 (2004-12-01), Hagmann et al.
patent: 2005/0192332 (2005-09-01), Barth et al.
patent: 2 783 246 (2000-03-01), None
patent: WO 00/46209 (2000-08-01), None
patent: WO 00/63204 (2000-10-01), None
patent: WO 00/69848 (2000-11-01), None
patent: WO 01/32663 (2001-05-01), None
patent: WO 03/027076 (2003-04-01), None
patent: WO 03/040107 (2003-05-01), None
patent: WO 03/063781 (2003-08-01), None
Barth, F. et al., “Preparation and Formulation of Tricyclic Heterocycles Containing a Pyrazole-3-Carboxamide Subunit for Pharmaceutical Use as Cannanbinoid Receptor Antagonists,”Chem. Abstr.134, 340504 (2001).
Bodanszky, M et al., “The Practice of Peptide Synthesis,” Springer-Verlag.; (ISBN: 0-387-57505-7) (2D ED. 1994).
Consroe, P., “Brain Cannabinoid Systems as Targets for the Therapy of Neurological Disorders,” Neurobiology of Disease 5:534-551 (1998).
Dutta, A. et al., “Synthesis and Characterization of Novel Derivative of 2-Aminotetralins: Development of Highly Selective Derivatives for the D3 Receptor,”Med. Chem Res.10(4):208-229 (2000).
Dyck, B. et al., “Potent Imidazole and Triazole CB1 Receptor Antagonists Related to SR141716,”Bioorganic&Medicinal Chemistry Letters14:1151-1154 (2004).
Felder, C. et al., “LY320135, A Novel Cannabinoid CB1 Receptor Antagonist, Unmasks Coupling of the CB1 Receptor to Stimulation of cAMP Accumulation,”Journal of Pharmacology and Experimental Therapeutics284(1):291-297 (1998).
Goya, P. et al., “Recent Advances in Cannabinoid Receptor Agonists and Antagonists,”Exp. Opin. Ther. Patents10(10):1529-1538 (2000).
Greenberg, D., “Cannabinoids and Neuroprotection in Stroke,”Drug News Perspect12(8):458-462 (1999).
Guillemet, M. et al., “A Simple Synthesis of New Push-Pull Substituted Imidazoles by Chemoselective Nucleophilic Attack of α-Cyano Epoxides,”Tetrahedron Letters, 36(4):547-548 (1995).
Hosohata, K. et al., “AM630 Is a Competitive Cannabinoid Receptor Antagonist in the Guinea Pig Brain,”Life Sciences, 61(9):115-118 (1997).
Kanyonyo, M. et al., “3-Alkyl-(5,5′-Diphenyl)Imidazolidinediones As New Cannabinoid Receptor Ligands,”Bioorganic&Medicinal Chemistry Letters9:2233-2236 (1999).
Khanna, I. et al., “1,2-Diarylimidazoles as Potent, Cyclooxygenase-2 Selective, and Orally Active Anti-inflammatory Agents,”J. Med. Chem.40:1634-1647 (1997).
Khanna, I. et al., “Selective Cyclooxygenase-2 Inhibitors: Heteroaryl Modified 1,2-Diarylimidazoles Are Potent, Orally Active Antiinflammatory Agents,”J. Med. Chem.43:3168-3185 (2000).
King, F.D., Ed., Medicinal Chemistry: Principles and Practice, p. 215 (1994), ISBN: 0-85186-494-5.
Kudo, N. et al., “Synthesis and Herbicidal Activity of 1,5-Diarylpyrazole Derivatives,”Chem. Pharm. Bull.47(6):857-868 (1999).
Lan, R. et al., “Structure—Activity Relationships of Pyrazole Derivatives as Cannabinoid Receptor Antagonists,”J. Med. Chem.42:769-776 (1999).
Landsman, R. et al., “SR141716A is an Inverse Agonist at the Human Cannabinoid CB1Receptor,”European Journal of Pharmacology344:R1-R2 (1997).
Li, Z. et al., “Facile Synthesis of Amidines Via Intermolecular Reductive Coupling of Nitriles with Azobenzene Promoted by Samarium Diiodide”,Chemical Abstracts133(18):1 (2000).
Matsuda, L. et al., “Cannabinoid Receptors: Which Cells, Where, How, and Why?,” NIDA Research Monograph, 48-56 (T. Lee, Ed.) (1992).
Matsuda, L. et al., “Molecular Biology of the Cannabinoid Receptor,”Academic Press, 117-140, (R. Pertwee, Ed.) (1995).
Matthews, W. et al., “Synthesis of [18F] SR144385: A Selective Radioligand for Positron Emission Tomographic Studies of Brain Cannabinoid Receptors,”J. Labelled Cpd. Radiopharm.42:589-596 (1999).
Mechoulam, R. et al., “Endocannabinoids,”Eur. J. Pharmacol.359:1-18 (1998).
Mechoulam, R. et al., “Towards Cannabinoid Drugs—Revisited,”J. Prog. Med. Chem. 35:199-243 (1998).
Mechoulam, R. et al., “Towards Cannabinoid Drugs,”J. Prog. Med. Chem. 24:159-207 (1987).
Meschler, J. et al., “Inverse Agonist Properties of N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide HCI (SR141716A) and 1-(2-Chlorophenyl)-4-cyano-5-(4-methoxyphenyl)-1H-pyrazole-3-carboxylic Acid Phenylamide (CP-272871) for the CB1Cannabinoid Receptor,”Biochem. Pharmacol.60:1315-1323 (2000).
Mignani, S. et al., “Preparation of 1-Bis(aryl)methyl-3-(alkylsulfonyl)arylmethyleneazetidines as Cannabinoid CB1Receptor Antagonists,”Chemical Abstracts132(18):699 (2000).
Munro, S. et al., “Molecular Characterization of a Peripheral Receptor for Cannabinoids,”Nature365:61-65 (1993).
Nakamura-Palacios, E. et al., “The Pharmacology of SR 141716A: A Review,”CNS Drug Review5(1):43-58 (1999).
Pertwee, R., “Cannabinoid Receptors and Pain,”Progress in Neurobiology63:569-611 (2001).
Pertwee, R., “Neuropharmacology and Therapeutic Potential of Cannabinoids,”Addiction Biology5:37-46 (2000).
Pertwee, R., “Pharmacology of Cannabinoid Receptor Ligands,”Current Medicinal Chemistry6:635-664 (1999).
Pertwee, R., “Cannabinoids and the Gastrointestinal Tract,”Gut48:859-867 (2001).
Pop, E., “Developing Cannabinoids as Potential Central Nervous System Agents,”Current Opinion in CPNS Investigational Drugs1(5):587-596 (1999).
Robson, P., “Therapeutic Aspects of Cannabis and Cannabinoids,”Journal of Psychiatry178:107-115 (2001).
Seifert, P. et al., “Einige Reaktionen and Derivaten von α-Ketosäuren und α-Ketosäureestern,”Helv. Chim. Acts33(99):725-736 (1950).
Smith, M. et al., “Crown Ether Complexes and Cryptates,”Advanced Organic Chemistry, 5thEd., pp. 105-109 (2001), John Wiley & Sons, New York, ISBN: 0471-585890.
Smith, M. et al., Advanced Organic Chemistry, 5thEd., pp. 215-217 (2001), John Wiley & Sons, New York, ISBN: 0471-585890.
Stella, V., “Prodrugs as Therapeutics,” Expert Opin. Ther. Patents, 14(3):277-280 (2004).
Thomas, B. F. et al., “Comparative Receptor Binding Analyses of Cannabinoid Agonists and Antagonists,”Journal of Pharmacology and Experimental Therapeutics285(1):285-292 (1998).
Tsuji, K. et al., “Studies on Anti-inflammatory Agents. IV.1)Synthesis and Pharmacological Properties of 1,5-Diarylpyrazoles and Related Derivatives,”Chem. Pharm. Bull.45(6):987-995 (1997).
Ueda, T. et al., “A Novel Ring Transformation of 5-Acylaminouracils and 5-Acylamino-Pyrimidin-4(3H)-Ones into Imidazoles,”Tetrahedron Letters29(36):4607-4610 (1988).
Wiley, J. et al., “Novel Pyrazole Cannabinoids: Insights into CB1Receptor Recognition and Activation,”J. Pharmacol. Exp. Ther.296(3):1013-1022 (200
Herremans Arnoldus H. J.
Kruse Cornelis G.
Lange Josephus H. M.
Stuivenberg Herman H. van
Finnegan Henderson Farabow Garrett & Dunner L.L.P.
Grazier Nyeemah
Solvay Pharmaceuticals B.V.
LandOfFree
1H-imidazole derivatives having CB1 agonistic, CB1 partial... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 1H-imidazole derivatives having CB1 agonistic, CB1 partial..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 1H-imidazole derivatives having CB1 agonistic, CB1 partial... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3534107